Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 58 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
83 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
INTERNATIONAL MEDICAL PRODUCTS from Sint-Gillis (bij-Brussel), company number BE0426041123, closed financial year 2025 with a result of € 984,307 after tax. For that financial year INTERNATIONAL MEDICAL PRODUCTS recorded revenue of € 23.8 million and equity of € 4.2 million. Compared with financial year 2024, the result moved from € 1 million to € 984,307. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
€ 4.2 million
▲ 30% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 984,307
▼ 2% vs 2024
Profit after tax over the fiscal year.
€ 327,570
▲ € 261,907 vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 3.1 million.
People and assets in 2025
16.3
▲ 0.3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.6 million
▲ 7% vs 2024
€ 101,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 3.1 million
▼ 39% vs 2024
Loans from banks and other lenders, long and short.
€ 2.2 million
▲ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 39 days on average.
€ 405,009
▼ 13% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 24,502,325 | € 25,718,708 | € 26,950,917 | € 23,753,212 | ▼ 12% |
| Profit after taxes | € -357,159 | € 1,120,283 | € 1,006,300 | € 984,307 | ▼ 2% |
| Equity | € 1,110,703 | € 2,229,815 | € 3,235,396 | € 4,219,021 | ▲ 30% |
| Total debts | € 9,614,812 | € 8,225,902 | € 7,662,486 | € 5,991,957 | ▼ 22% |
| Cash | € 400,163 | € 215,689 | € 65,662 | € 327,570 | ▲ € 261,907 |
| Land & buildings | € 106,274 | € 106,274 | € 84,337 | € 79,561 | ▼ 6% |
| Retained profit | € -33,067 | € 1,087,216 | € 2,093,516 | € 3,077,822 | ▲ 47% |
| Bank debt | € 5,233,447 | € 4,985,763 | € 4,974,678 | € 3,056,476 | ▼ 39% |
| Balance sheet total | € 10,742,593 | € 10,457,479 | € 10,899,273 | € 10,212,025 | ▼ 6% |
| Employees (FTE) | 17.4 | 16.3 | 16 | 16.3 | ▲ 0.3 |
Key figures of INTERNATIONAL MEDICAL PRODUCTS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to INTERNATIONAL MEDICAL PRODUCTS?
What happened at INTERNATIONAL MEDICAL PRODUCTS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- JESSICA WEVE stepped down as director. NBB
- NATALIS DEVELOPPEMENT SAS stepped down as director. NBB
- MB SOLUTIONS SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 984,307 (▼ 2% vs 2024). Source: NBB ↗
- NATALIS DEVELOPPEMENT SAS became a director. NBB
- JESSICA WEVE became a director. NBB
- MB SOLUTIONS SRL became a director. NBB
- New establishment in Sint-Gillis (bij-Brussel). KBO
In short
From € 357,159 loss in 2022 to € 984,307 profit in 2025.
Paid € 30,694 in corporate taxes since 2022.
Best year ever: 2023, with € 1.1 million profit.
Pays suppliers within 39 days on average.
A new publication or filing at INTERNATIONAL MEDICAL PRODUCTS? We notify you, reason included.
Follow INTERNATIONAL MEDICAL PRODUCTSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by MEDIPREMA GROUP (100%). It owns 100% of BELDICO BV, 54% of BELDICO SA and 50% of BELDICO FRANCE SAS itself.
Directors
According to the 2025 annual accounts
since 2025 · until 2031
Managing director · represented by Vincent Camus
since 2026 · until 2031
Director · represented by MARC BEMELMANS
Also active at: BELGIAN DIAGNOSTIC COMPANY
since 2025 · until 2031
Shareholders
MEDIPREMA GROUP
100%
Participations
Establishments
Establishment units
Physical locations of this company
Marcel Broodthaersplein 8 box 5
1060 Sint-Gillis (bij-Brussel)
Aye, Rue André Feher 5
6900 Marche-en-Famenne
Active since 22 April 2002
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 83 companies are registered at this address.
All companies at this address →Thalie
€ 2 million gross margin · 2026
DIENST VOOR TOERISME DER SPOORMANNEN - OFFICE DE TOURISME DES CHEMINOTS
Elbi
€ 1.5 million gross margin · 2026
REICO
€ 3,653 revenue · 2025
SOCIETE GABRIELLE
€ 388,904 gross margin · 2026
+78 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0426.041.123
- VAT number
- BE 0426.041.123
- Registered office
- Marcel Broodthaersplein 8 bus 5, 1060 Sint-Gillis (bij-Brussel)
- Names & denominations
- INTERNATIONAL MEDICAL PRODUCTS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 3 August 1984
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Detailhandel in medische en orthopedische artikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels